GCB and 34 CD5(+)/CD10(‐) non‐GCB DLBCL. Karyotype was successfully assessed in 43%, BCL2, BCL6, MYC abnormalities were found in 65%, 30%, and 26% in CD5(+)/CD10(+), and in 66%, 70%, and… Click to show full abstract
GCB and 34 CD5(+)/CD10(‐) non‐GCB DLBCL. Karyotype was successfully assessed in 43%, BCL2, BCL6, MYC abnormalities were found in 65%, 30%, and 26% in CD5(+)/CD10(+), and in 66%, 70%, and 23% in CD5(+)/CD10(‐), respectively, of cases. BCL2 overexpression by FCM was found in 58% of both DLBCL subgroups. Complete response was achieved in 65% of CD5(+)/CD10(+), and 66% of CD5(+)/CD10(‐) pts. Five‐year PFS was 46% [95%C.I.(30%,62%)] and 75% [95%C.I. (70%,80%)] for CD5(+) and CD5(‐)DLBCL, respectively (P = ,0003) (Figure 1A). 5‐year OS was 54% [95%C.I.(39%,70%)] and 81% [95%C. I.(76%,86%)] for CD5(+) and CD5(‐) DLBCL, respectively (P = .003) (Figure 1B). Conclusions: Detection of CD5/CD10/BCL2 expression by means of FNAB/FCM procedure completed within 1.5 hour appears as reliable/easy and cost‐effective method for diagnosing CD5(+) DLBCL with BCL2 overexpression compared with routine but less sensitive immunohistochemistry method. Both CD5(+)DLBCL subgroups have worse prognosis compared to CD5(‐)DLBCL. Future studies should investigate novel therapeutic strategies in these high risk pts.